PTPN1 and obesity due to melanocortin 4 receptor deficiency: Several PTP1B inhibitors, including ertiprotafib, trodusquemine and ABBV-CLS-484, have, however, successfully reached phase I and II clinical trials for the treatment of diabetes and obesity, and new, highly specific therapeutic PTP1B inhibitors continue to be explored [16,17].